MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages

Toxicology in Vitro

Volumn 24, Issue 3, 2010, Pages 745-750

  Perez, Anne ^a   Wright, Matthew B ^a   Maugeais, Cyrille ^a   Braendli Baiocco, Annamaria ^a   Okamoto, Hiroshi ^b   Takahashi, Akemi ^b   Singer, Thomas ^a   Mueller, Lutz ^a   Niesor, Eric J ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b JAPAN TOBACCO INC   (Japan)

Author keywords

CETP; Dalcetrapib; Macrophage; MARCO; Scavenger receptor

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; CHYLOMICRON; DALCETRAPIB; MACROPHAGE RECEPTOR WITH COLLAGENOUS DOMAIN PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; RO 4607381; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR AI; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LAMINA PROPRIA; LIPID TRANSPORT; MACROPHAGE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE;

AMINO ACID OXIDOREDUCTASES; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOTTING, WESTERN; CELL LINE; CHOLESTEROL, VLDL; CHYLOMICRONS; CPG ISLANDS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-4; LIPID METABOLISM; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, INBRED C57BL; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RNA; SULFHYDRYL COMPOUNDS; TH1 CELLS;

RATTUS; RODENTIA;

EID: 77649187280     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.01.002     Document Type: Article

References (22)

1. Bowdish D.M.E., Sakamoto K., Kim M.-J., Kroos M., Mukhopadhyay S., Leifer C.A., Tryggvason K., Gordon G., and Russell D.G. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and mycobacterium tuberculosis. PLoS Pathog 5 (2009) e1000474 10.1371/journal.ppat.1000474
2. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., van Tol A., and Kastelein J.J. Efficacy and safety of a novel cholesterol ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
3. Derks M., Fowler S., and Kuhlmann O. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clinical Therapeutics 31 (2009) 586-599
4. Elomaa O., Kangas M., Sahlberg C., Tuukkanen J., Sormunen R., Liakka A., Thesleff I., Kraal G., and Tryggvason K. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell 80 (1995) 603-609
5. Elshourbagy N.A., Li X., Terrett J., Vanhorn S., Gross M.S., Adamou J.E., Anderson K.M., Webb C.L., and Lysko P.G. Molecular characterization of a human scavenger receptor, human MARCO. European Journal of Biochemistry 267 (2000) 919-926
6. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. National Heart, Lung, Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
7. Guerin M., Le Goff W., Duchene E., Julia Z., Nguyen T., Thuren T., Shear C.L., and Chapman M.J. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology 28 (2008) 148-154
8. Józefowski S., Arredouani M., Sulahian T., and Kobzik L. Disparate regulation and function of the class A scavenger receptors SR-AI/II and MARCO. Journal of Immunology 175 (2005) 8032-8041
9. Kangas M., Brännström A., Elomaa O., Matsuda Y., Eddy R., Shows T.B., and Tryggvason K. Structure and chromosomal localization of the human and murine genes for the macrophage MARCO receptor. Genomics 58 (1999) 82-89
10. Kramer J.L., Baltathakis I., Alcantara O.S., and Boldt D.H. Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (WAF1/CIP1) and requires iron. British Journal Haematology 117 (2002) 727-734
11. Kuivenhoven J.A., de Grooth G.J., Kawamura H., Klerkx A.H., Wilhelm F., Trip M.D., and Kastelein J.J. Effectiveness of inhibition of cholesterol ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. American Journal of Cardiology 95 (2005) 1085-1088
12. Lysko P.G., Weinstock J., Webb C.L., Brawner M.E., and Elshourbagy N.A. Identification of a small-molecule, nonpeptide macrophage scavenger receptor antagonist. The Journal of Pharmacology and Experimental Therapeutics 289 (1999) 1277-1285
13. Moore K.J., and Freeman M.W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arteriosclerosis, Thrombosis, and Vascular Biology 26 (2006) 1702-1711
14. Moriwaki H., Kume N., Kataoka H., Murase T., Nishi E., Sawamura T., Masaki T., and Kita T. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Letters 440 (1998) 29-32
15. Moriwaki H., Kume N., Sawamura T., Aoyama T., Hoshikawa H., Ochi H., Nishi E., Masaki T., and Kita T. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology 18 (1998) 1541-1547
16. Mukhopadhyay S., Chen Y., Sankala M., Peiser L., Pikkarainen T., Kraal G., Tryggvason K., and Gordon S. MARCO, an innate activation marker of macrophages, is a class A scavenger receptor for Neisseria meningitidis. European Journal of Immunology 36 (2006) 940-949
17. Niesor, E.J., von der Marck, E., Brousse, M., Maugeais, C., 2008. Inhibition of cholesterol ester transfer protein (CETP): different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR). Atherosclerosis, doi:10.1016/j.atherosclerosis.2008.04.024.
18. Okamoto H., Iwamoto Y., Maki M., Sotani T., Yonemori F., and Wakitani K. Effect of JTT-705 on cholesterol ester transfer protein and plasma lipid levels in normolipidemic animals. European Journal of Pharmacology 466 (2003) 147-154
19. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. Journal of Clinical Investigation 116 (2006) 3090-3100
20. Seager Danciger J., Lutz M., Hama S., Cruz D., Castrillo A., Lazaro J., Phillips R., Premack B., and Berliner J. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. Journal of Immunological Methods 288 (2004) 123-134
21. Stein E.A., Stroes E.S.G., Steiner G., Buckley B.M., Capponi A.M., Burgess T., Niesor E.J., Kallend D., and Kastelein J.J.P. Safety and tolerability of dalcetrapib. American Journal of Cardiology 104 (2009) 82-91
22. van der Laan L.J., Döpp E.A., Haworth R., Pikkarainen T., Kangas M., Elomaa O., Dijkstra C.D., Gordon S., Tryggvason K., and Kraal G. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. Journal of Immunology 162 (1999) 939-947